Thesis:

IEH Corporation (Market Cap: $23.10M; Price: $9.50) is a U.S.-based manufacturer specializing in printed circuit board (PCB) connectors and custom interconnects, leveraging its proprietary Hyperboloid contact technology. These high-performance connectors are engineered for mission-critical applications in defense, aerospace, medical, and space industries, where reliability in extreme environments is essential.

Despite a recent operating loss from customer delays and the slow recovery of commercial aircraft, management remains confident in IEH’s long-term trajectory. Defense demand, the company’s largest market, remains strong, with over $2.5 million in recent orders for programs like PATRIOT, AMRAAM, and LTMADS, while the commercial space launch business continues to expand, and commercial aerospace is expected to return to pre-COVID levels.

Margins are projected to improve as recent price increases begin to offset rising costs, with management noting that demand has remained resilient despite the adjustments. IEHC targets a return to pre-COVID gross margins of 30–35%, up from current levels of around 15%.

The company’s substantial manufacturing capacity at its Brooklyn and Allentown facilities further supports growth, enabling scalable production without the need for immediate capital expenditures.

Financially, IEH maintains a strong position with a debt-free balance sheet and $9 million in cash, providing the flexibility to pursue both organic growth and strategic acquisitions.

Valuation Range:

IEHC is currently unprofitable on a net income basis, and there are no analyst estimates available for FY2026. However, if management can improve gross margins and restore profitability to pre-COVID levels, the company could potentially generate $2.5–5.0 million in net income, similar to its performance from 2017 to 2019. This would imply a PE multiple in the range of approximately 4.6x to 9.2x.

Key Risks:

The primary risk for IEHC lies in successfully executing its growth strategy and returning to consistent profitability. While the company has hovered around break-even since COVID and has yet to fully recover, its substantial cash reserves provide a buffer to support operations and strategic initiatives during this transition.

DD Checklist: